Drug profile · INN
carfilzomib
KYPROLIS
carfilzomib (KYPROLIS) is a 26s proteosome inhibitor. Associated with Amgen. Route of administration: injection. Current US regulatory status: approved.
Drug details — carfilzomib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 25
- Data quality
- 0.89
Quick answer
carfilzomib (KYPROLIS) is a 26s proteosome inhibitor. Associated with Amgen. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
26S proteosome inhibitor
Primary target: 26S proteasome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is carfilzomib?
carfilzomib (KYPROLIS) is a 26s proteosome inhibitor. Associated with Amgen. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for carfilzomib?
KYPROLIS is a marketed brand name for carfilzomib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of carfilzomib?
carfilzomib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.